文献速递皮肤肿瘤

瑞典1990至2020年黑色素瘤发病率与生存趋势变化

Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden.
PubMed 文献 · Br J Dermatol · 2023-01-01

该研究基于瑞典黑色素瘤登记处(SweMR)全国性、人群基础、前瞻性收集的1990至2020年侵袭性皮肤黑色素瘤临床病理数据,分析发病率与黑色素瘤特异性生存(MSS)的时间趋势。结果显示5年MSS由1990-2000年的88.9%升至2011-2020年的93.0%,男女及各年龄组死亡风险在最近诊断期均显著降低。

要点

  • 5年MSS从1990-2000年的88.9%升至2011-2020年的93.0%
  • 2011-2020年男性HR 0.62、女性HR 0.62(均vs 1990-2000)
  • 结节型黑色素瘤诊断比值比相对1990-2000年降低20%(2001-2010)和46%(2011-2020)

核心结论

  • 瑞典男女的黑色素瘤特异性生存均改善,2011-2020年的改善可能与新型系统治疗引入相关,并首次在瑞典被详细展示。

研究设计与样本

  • 全国性、人群基础、前瞻性收集的瑞典黑色素瘤登记处(SweMR)侵袭性皮肤黑色素瘤临床病理数据分析,采用Kaplan-Meier曲线与Cox比例风险比分析1990至2020年生存趋势。
  • 1990至2020年间瑞典70 511例患者共诊断77 036例原发性侵袭性皮肤黑色素瘤。

主要发现

  • 5年MSS(95%CI)为1990-2000年88.9%(88.3-89.4)、2001-2010年89.2%(88.7-89.6)、2011-2020年93.0%(92.7-93.9)。
  • 诊断为结节型黑色素瘤(vs 浅表扩散型)的比值比相对1990-2000年显著降低20%(2001-2010)和46%(2011-2020)。
  • 总体MSS相对1990-2000年在两个诊断期均改善:男性HR 2001-2010为0.89(95%CI 0.82-0.96)、2011-2020为0.62(95%CI 0.56-0.67);女性HR 2001-2010为0.82(95%CI 0.74-0.91)、2011-2020为0.62(95%CI 0.56-0.70)。
  • 最近诊断期(2011-2020 vs 1990-2000)男女所有年龄组的黑色素瘤死亡风险均显著降低。

临床怎么用

  • 研究结果强调瑞典男女黑色素瘤特异性生存改善,2011-2020年的改善可能与新型系统治疗引入相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Melanoma-specific survival (MSS) is heterogenous between stages and is highly dependent on the T stage for primary localized disease. New systemic therapies for metastatic cutaneous melanoma (CM) have been introduced since 2012 in Sweden. OBJECTIVES: To analyse the incidence and MSS time trends between 1990 and 2020 in Sweden. METHODS: Nationwide, population-based and prospectively collected clinico-pathological data on invasive CM from the Swedish Melanoma Registry (SweMR) were analysed for survival trends between 1990 and 2020 using Kaplan-Meier curves and Cox proportional hazard ratios (HRs). RESULTS: In total, 77 036 primary invasive CMs were diagnosed in 70 511 patients in Sweden between 1990 and 2020. The 5-year MSS [95% confidence interval (CI)] was 88.9% (88.3-89.4) for 1990-2000, 89.2% (88.7-89.6) for 2001-2010 and 93.0% (92.7-93.9) for 2011-2020. The odds ratios for being diagnosed with nodular melanoma (vs. superficial spreading melanoma) was significantly reduced by 20% (2001-2010) and by 46% (2011-2020) vs. the reference period 1990-2000. Overall, the MSS improved over both diagnostic periods (2001-2010 and 2011-2020) vs. the reference period 1990-2000 among men and women, respectively [HRmen: 2001-2010: 0.89 (95% CI 0.82-0.96) and 2011-2020: 0.62 (95% CI 0.56-0.67); HRwomen: 2001-2010: 0.82 (95% CI 0.74-0.91) and 2011-2020: 0.62 (95% CI 0.56-0.70)]. The risk of death from CM was significantly lower in all age groups for both men and women in the most recent diagnostic period (2011-2020 vs.1990-2000). CONCLUSIONS: The results emphasize the improved MSS among men and women in Sweden. The MSS improvements, specifically for the period 2011-2020, may be correlated to the introduction of new systemic therapies and are here shown for the first time in detail for Sweden.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Vikström S, Mikiver R, Lapins J, et al. Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden. Br J Dermatol. 2023. PMID: 37463416. doi:10.1093/bjd/ljad244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。